Post-Genomic Technologies

CeMM has invested in the development of a suite of tools and technologies in order to accelerate our understanding of the cause of disease and the identification of new and more effective treatments. These technologies are being used both by groups at CeMM as well as by national and international collaborators.

The Biomedical Sequencing Facility (BSF)  

The BSF is Austria’s first technology platform dedicated to next generation sequencing in biomedicine. It is part of the joint genomics core facility of the Medical University of Vienna and CeMM. It is coordinated by Christoph Bock, and offers:

  • Sequencing using the Illumina HiSeq platform (currently the preferred technology for many applications).

  • Advice and contacts for other sequencing technologies (e.g. Ion Torrent, Roche 454, Pacific Biosciences, Illumina MiSeq, Complete Genomics).

  • Library preparation services.

  • Bioinformatic data processing, analysis and assistance with data interpretation.

Mass spectrometry

Mass spectrometry is a critical component of several projects at CeMM, including those involving:

  • Protein-protein interactions to generate comprehensive protein interactomes.

  • Drug-protein interactions.

  • Quantitative expression proteomics for the relative and comparative quantitative analysis of global proteomes.

  • Monitoring the role of post-translational modifications in cell signalling pathways.


Jörg Menche's group

Network Medicine

Recent advances in high-throughput technologies have created exciting new opportunities for systematically investigating the molecular basis of human disease. CeMM researchers employ a broad range of powerful post-genomic technologies, from next-generation sequencing of genomes, epigenomes and transcriptomes, to high-throughput proteomics and chemical screening. The group of Jörg Menche applies diverse computational approaches to help understand and interpret the large datasets derived from these technologies. 

Platform Austria for Chemical Biology (PLACEBO)

PLACEBO is a comprehensive chemical screening platform that enables researchers to identify and characterize small molecules for studying biological processes and developing new drugs. It was initiated as a partnership between CeMM and seven other Austrian research groups, funded under the Gen-AU program of the Austrian Ministry of Science and Research. The project has developed into a long-term initiative open to the wider scientific community on a collaborative basis.

PLACEBO is headed by Stefan Kubicek and provides access to chemical biology resources including

  •  A 92,000 compound library

  • High-throughput and high-content screening

  • Chemical proteomics


Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives

Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives

The Christian Doppler Laboratory, headed by Stefan Kubicek, is a public-private partnership between CeMM, Boehringer Ingelheim GmbH, and Haplogen GmbH. It uses the resources established in the PLACEBO project to develop novel screening technologies and identifying chemical probe compounds for future drug development projects.

In the chemical epigenetics module, technologies are developed to identify and characterize small molecules and druggable proteins regulating chromatin structure and function, in collaboration with Boehringer Ingelheim. In addition, chemical probes for host factors of infectious diseases are identified based on molecular targets derived by a powerful screening approach using human haploid cells implemented at Haplogen GmbH. These targets are brought together with CeMM’s comprehensive compound library and screening expertise to generate novel chemical probes that can be used for proof-of-concept studies.